Central Line-associated Bloodstream Infection Prevention Using TauroLock-Hep100 in Pediatric Oncology Patients. (CATERPILLAR)
Central Line-associated Bloodstream Infection (CLABSI)
About this trial
This is an interventional prevention trial for Central Line-associated Bloodstream Infection (CLABSI) focused on measuring Central Line-associated Bloodstream Infection, Paediatric oncology patients, Central venous access device
Eligibility Criteria
Inclusion Criteria: Age between 0 - <19 years Radiological, cytological or histological proven paediatric malignancy (hematologic, solid, and neurologic malignancies) Tunnelled external central venous access device or totally implantable venous access port to be inserted at the Princess Máxima Center for Pediatric Oncology Planned central venous access device insertion of >90 days Written consent signed according to local law and regulations Parents/guardians or patient are willing and able to comply with the trial procedure Exclusion Criteria: A previous central venous access device removed < 12 months ago. Expected treatment for a majority of the follow-up time in a different hospital than the Princess Maxima Center for pediatric oncology in the first 90 days of inclusion resulting in difficulties/the inability to visit the Princess Maxima Center at least once every 3 weeks. Primary immunological disorder Contra indications: known hypersensitivity to taurolidine, citrate or heparin, and a history of heparin-induced thrombocytopenia. Documented bacteremia in the period from 24h before catheter insertion until inclusion
Sites / Locations
- Princess Máxima Center for Pediatric OncologyRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
TauroLock-Hep100 (taurolidine 1.35%, citrate 4%, heparin 100 IU/mL)
Heparin lock (heparin 100 IU/mL)